Cargando…

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT

BACKGROUND: A nadir Prostate-Specific Antigen (nPSA) of 0.06 ng/mL has been shown to be a strong independent predictor of biochemical recurrence-free survival (bRFS) in patients with intermediate or high-risk (HR) prostate cancer treated with definitive external beam radiation therapy (RT) and andro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayoub, Zeina, Khader, Jamal, Bulbul, Muhammad, Khauli, Raja B., Andraos, Therese Y., Shamseddine, Ali, Mukherji, Deborah, Geara, Fady B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743609/ https://www.ncbi.nlm.nih.gov/pubmed/36503556 http://dx.doi.org/10.1186/s12894-022-01145-x

Ejemplares similares

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

The impact of hegemonic masculine ideals on self‐esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT‐naïve patients
por: Gentili, Caterina, et al.
Publicado: (2022)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

Transport of ADT
por: Juha Sakkinen
Publicado: (2006)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

ADT and OBSBOX in 2016
por: Valuch, D, et al.
Publicado: (2017)

Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

ADT fast losses MD
por: Priebe, A, et al.
Publicado: (2013)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model
por: Shen, Ying-Chun, et al.
Publicado: (2017)

WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
por: Gamulin, Marija, et al.
Publicado: (2019)

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
por: Choi, Erin, et al.
Publicado: (2022)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

ADT and RF after LS1
por: Butterworth, A, et al.
Publicado: (2015)

Weniger Corona-Infektionen unter ADT?
por: Bublak, Robert
Publicado: (2020)

Bridging Arrays and ADTs in Recursive Proofs
por: Fedyukovich, Grigory, et al.
Publicado: (2021)

Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
por: Yang, Xiangwei, et al.
Publicado: (2022)

The LHC Transverse Damper (ADT) Performance Specification
por: Boussard, Daniel, et al.
Publicado: (2000)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study
por: Braga-Basaria, Milena, et al.
Publicado: (2023)

Noise studies with new ADT pickups (MD4143)
por: Buffat, Xavier, et al.
Publicado: (2019)

Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
por: Ito, Tetsuro, et al.
Publicado: (2018)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)
por: Skolarus, Ted A., et al.
Publicado: (2018)

Emittance growth in collision with optimised ADT settings (MD3291)
por: Buffat, Xavier, et al.
Publicado: (2019)

Active halo control through narrow-band excitation with the ADT
por: Wagner, Joschka, et al.
Publicado: (2016)

ADT and Obsbox in LHC Run 2, Plans for LS2
por: Söderén, M, et al.
Publicado: (2019)

AB17. ADT treatment promotes PCa EMT and metastasis
por: Niu, Yuan-Jie
Publicado: (2014)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

MD4036: New ADT signal processing for large tune acceptance
por: Komppula, Jani Paavo Olavi, et al.
Publicado: (2019)

FedADT: An Adaptive Method Based on Derivative Term for Federated Learning
por: Gao, Huimin, et al.
Publicado: (2023)

Impact of the ADT on the beam quality with high brightness beams in collision (MD2155)
por: Buffat, Xavier, et al.
Publicado: (2018)

The effect of strength training on muscle cellular stress in prostate cancer patients on ADT
por: Nilsen, T S, et al.
Publicado: (2016)

ADT-G as a promising biomarker for peripheral hyperandrogenism in adult female acne
por: Rocha, Marco, et al.
Publicado: (2017)

Palliative TURP Combined with Intermittent ADT Is A Curative Therapy to Some Elderly Men with Localized Prostate Adenocarcinoma
por: Zhang, Xu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lamli8tigp1qlh2rbvfs46rcav